Advertisement

CNS Drugs

, Volume 31, Issue 1, pp 51–64 | Cite as

Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention

  • Rama M. Kamal
  • Martijn S. van Noorden
  • Wim Wannet
  • Harmen Beurmanjer
  • Boukje A. G. Dijkstra
  • Arnt Schellekens
Review Article

Abstract

The misuse of γ-hydroxybutyrate (GHB) for recreational purposes has resulted in an increase in GHB-related problems such as intoxications, dependence and withdrawal in several countries in Europe, Australia and the US over the last decade. However, prevalence rates of misuse of GHB and its precursor, γ-butyrolactone (GBL), are still relatively low. In this qualitative review paper, after a short introduction on the pharmacology of GHB/GBL, followed by a summary of the epidemiology of GHB abuse, an overview of GHB dependence syndrome and GHB/GBL withdrawal syndrome is provided. Finally, the existing literature on management of GHB detoxification, both planned and unplanned, as well as the available management of GHB withdrawal syndrome, is summarized. Although no systematic studies on detoxification and management of withdrawal have been performed to date, general recommendations are given on pharmacological treatment and preferred treatment setting.

Keywords

Baclofen Withdrawal Symptom Relapse Prevention Withdrawal Syndrome Sodium Oxybate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Compliance with Ethical Standards

Conflict of interest

The authors Rama Kamal, Martijn van Noorden, Wim Wannet, Harmen Beurmanjer, Boukje Dijkstra and Arnt Schellekens declare that they have no conflicts of interest related to this review.

Funding

There was no external funding received for the preparation of this manuscript.

References

  1. 1.
    Galloway GPFS, Staggers FE Jr, Gonzales M, Stalcup SA, Smith DE. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction. 1997;92(1):89–96.PubMedCrossRefGoogle Scholar
  2. 2.
    Bramness J, Haugland S. Abuse of γ-hydroxybutyrate. Tidsskr Nor Laegeforen. 2011;131(21):2122–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Carter LP, Pardi D, Gorsline J, Griffiths R. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug Alcohol Depend. 2009;104(1–2):1–10.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Craig K, Gomez HF, McManus JL, Bania T. Sever gamma-hydroxybutyrate witdrawal: a case report and literature review. J Emerg Med. 2000;18(1):65–70.PubMedCrossRefGoogle Scholar
  5. 5.
    Drasbek K, Christensen J, Jensen K. Gamma-hydroxybutyrate—a drug of abuse. Acta Neurol Scand. 2006;114(3):145–56.PubMedCrossRefGoogle Scholar
  6. 6.
    Dyer J, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med. 2001;37(2):147–53.PubMedCrossRefGoogle Scholar
  7. 7.
    Gonzallez A, Nutt DJ. Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol. 2005;19(2):195–204.CrossRefGoogle Scholar
  8. 8.
    Hernandez M, McDaniel CH, Costanza CD, Hernandez OJ. GHB-induced delirium: a case report and review of the literature of gamma hydroxybutyric acid. Am J Drug Alcohol Abuse. 1998;24(1):179–83.PubMedCrossRefGoogle Scholar
  9. 9.
    McDonough M, Kennedy N, Glasper A, Bearn J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend. 2004;75(1):3–9.PubMedCrossRefGoogle Scholar
  10. 10.
    van Amsterdam JG, Brunt T, McMaster M, Niesink R. Possible long-term effects of gamma-hydroxybutyric acid (GHB) due to neurotoxicity and overdose. Neurosci Biobehav Rev. 2012;36(4):1217–27.PubMedCrossRefGoogle Scholar
  11. 11.
    Zvosec DL, Smith SW, Porrata T, Strobl AQ, Dyer JE. Case series of 226 gamma-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am J Emerg Med. 2011;29(3):319–32.PubMedCrossRefGoogle Scholar
  12. 12.
    Miotto K, Darakjian J, Basch J, Murray S, Zogg J, Rawson R. Gammahydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict. 2001;10:232–41.PubMedCrossRefGoogle Scholar
  13. 13.
    Snead O, Gibson KM. g-Hydroxybutyric acid. N Engl J Med. 2005;352(26):2721–32.PubMedCrossRefGoogle Scholar
  14. 14.
    Wong CG, Chan KF, Gibson KM, Snead O. Gamma-hydroxybutyric acid: neurobiology and toxicology of a recreational drug. Toxicol Rev. 2004;23(1):3–20.PubMedCrossRefGoogle Scholar
  15. 15.
    Crunelli V, Emri Z, Leresche N. Unravelling the brain targets of gamma-hydroxybutyric acid. Curr Opin Pharmacol. 2006;6(1):44–52.PubMedCrossRefGoogle Scholar
  16. 16.
    Kam P, Yoong F. Gamma-hydroxybutyric acid : an emerging recreational drug. Anaesthesia. 1998;53(12):1195–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Mamelak M. Narcolepsy and depression and the neurobiology of gammahydroxybutyrate. Prog Neurobiol. 2009;89(2):193–219.PubMedCrossRefGoogle Scholar
  18. 18.
    Gallimberti L, Schifano F, Forza G, Miconi L, Ferrara SD. Clinical efficacy of gamma-hydroxybutyric acid in treatment of opiate withdrawal. Eur Arch Psychiatry Clin Neurosci. 1994;244(3):113–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Gallimberti L, Spella MR, Soncini CA, Gessa GL. Gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence. Alcohol. 2000;20(3):257–62.PubMedCrossRefGoogle Scholar
  20. 20.
    WHO: Expert Committee on Drug Dependence Thirty-fifth Meeting. Gamma-hydroxybutyric acid (GHB) critical review report. Hammamet: World Health Organisation; 2012.Google Scholar
  21. 21.
    Pazos D, Giannasi P, Rossy Q, Esseiva P. Combining Internet monitoring processes, packaging and isotopic analyses to determine the market structure: example of gamma butyrolactone. Forensic Sci Int. 2013;230(1–3):29–36.PubMedCrossRefGoogle Scholar
  22. 22.
    EMCDDA. Report on the risk assessment of GHB in the framework of the joint action on new synthetic drugs. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2002.Google Scholar
  23. 23.
    Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Megarbane B. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila). 2012;50(6):458–70.CrossRefGoogle Scholar
  24. 24.
    Arena C, Fung HL. Absorption of sodium gamma-hydroxybutyrate and its prodrug gamma-butyrolactone: relationship between in vitro transport and in vivo absorption. J Pharm Sci. 1980;69:356–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Oliveto A, Gentry WB, Pruzinsky R, Gonsai K, Kosten TR, Martell B, Poling J. Behavioral effects of gamma-hydroxybutyrate in humans. Behav Pharmacol. 2010;21(4):332–42.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Felmlee MA, Roiko SA, Morse B, Morris M. Concentration-effect relationships for the drug of abuse gamma-hydroxybutyric acid. J Pharmacol Exp Ther. 2010;333(3):764–71.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Brenneisen R. Pharmacokinetics and excretion of gamma-hydroxybutryate (GHB) in healthy subjects. GHB J Anal Toxicol. 2004;28:625–30.PubMedCrossRefGoogle Scholar
  28. 28.
    Busardò FP, Jones AW. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol. 2015;13:47–70.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Hechler V, Gobaille S, Bourguignon JJ, Maitre M. Extracellular events induced by gamma-hydroxybutyrate in striatum: a microdialysis study. J Neurochem. 1991;56(3):938–44.PubMedCrossRefGoogle Scholar
  30. 30.
    Bay T, Eghorn LF, Klein AB, Wellendorph P. GHB receptor targets in the CNS: Focus on high-affinity binding sites. Biochem Pharmacol. 2014;87:220–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Vogensen SB, Marek A, Bay T, Wellendorph P, Kehler J, Bundgaard C, Frølund B, Pedersen MHF, Clausen RP. New synthesis and tritium labeling of a selective ligand for studying high-affinity γ-hydroxybutyrate (GHB) binding sites. J Med Chem. 2013;56(20):8201–5.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Greiner C, Röhl JE, Ali-Gorji, Wassmann H, Speckmann EJ. Different actions of gamma-hydroxybutyrate: a critical outlook. Neurol Res. 2003;25(27):759–63.PubMedCrossRefGoogle Scholar
  33. 33.
    Nava F, Carta G, Bortolato M, Gessa GL. g-Hydroxybutyric acid and baclofen decrease extracellular acetylcholine levels in the hippocampus via GABA receptors. Eur J Pharm. 2001;430:261–3.CrossRefGoogle Scholar
  34. 34.
    Abanades S, Farre M, Segura M, Pichini S, Barral D, Pacifici R, Pellegrini M, Fonseca F, Langohr K, De La Torre R. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann NY Acad Sci. 2006;1074:559–76.PubMedCrossRefGoogle Scholar
  35. 35.
    Wong C, Gibson K, Snead O. From the street to the brain: neurobiology of the recreational drug γ-hydroxybutyric acid. Trends Pharmacol Sci. 2004;25(1):29–34.PubMedCrossRefGoogle Scholar
  36. 36.
    Hefele B, Naumann N, Trollmann R, Dittrich K, Rascher W. Fast-in, fast-out. Lancet. 2009;373:9672.CrossRefGoogle Scholar
  37. 37.
    Kamal RM, van Noorden MS, Franzek E, Dijkstra BA, Loonen AJ, De Jong CA. The neurobiological mechanisms of gamma-hydroxybutyrate dependence and withdrawal and their clinical relevance: a review. Neuropsychobiology. 2016;73(2):65–80.PubMedCrossRefGoogle Scholar
  38. 38.
    Dines AM, Wood DM, Christopher Yates C, Heyerdahl F, Hovda KE, Giraudo I, Sedefov R, Dargan PI, Euro-DEN Research Group. Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN). Clin Toxicol. 2015;53(9):893–900.CrossRefGoogle Scholar
  39. 39.
    Zvosec D, Smith S, Hall B. Three deaths associated with use of Xyrem. Sleep Med. 2009;10(4):490–3.PubMedCrossRefGoogle Scholar
  40. 40.
    Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379(9810):55–70.PubMedCrossRefGoogle Scholar
  41. 41.
    Krul J, Girbes AR. γ-Hydroxybutyrate: experience of 9 years of γ-hydroxybutyrate (GHB)-related incidents during rave parties in The Netherlands. Clin Toxicol (Phila). 2011;49(4):311–5.CrossRefGoogle Scholar
  42. 42.
    Kapoor P, Deshmukh R, Ipsita Kukreja I. GHB acid: a rage or reprive. J Adv Pharm Technol Res. 2013;4(4):173–8.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Australian Institute o, Health, and, Welfare. National drug strategy household survey detailed report 2014. In: Drug statistics series, vol. 28. Canberra: AIHW; 2014.Google Scholar
  44. 44.
    NIDA: Monitoring the Future Study. Trends in prevalence of various drugs, club drugs. In: National Institute on Drug Abuse. 2015.Google Scholar
  45. 45.
    NSDUH. Results from the 2013 National Survey on Drug Use and Health. In: http://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs2013/NSDUH-DetTabs2013.htm#tab7.22b. 2013.
  46. 46.
    EMCDDA. GHB and its precursors—EU drugs reports emerging trend study. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2008.Google Scholar
  47. 47.
    EMCDDA. New psychoactive substances: an update from the EU Early Warning System. Luxembourg: Publications Office of the European Union; 2015c.Google Scholar
  48. 48.
    Theodore PS, Durán RE, Antoni MH. Drug use and sexual risk among gay and bisexual men who frequent party venues. AIDS Behav. 2014;18:2178–86.PubMedCrossRefGoogle Scholar
  49. 49.
    Bourne A, Reid D, Hickson F, Torres Rueda S, Weatherburn P. The Chemsex Study: drug use in sexual settings among gay and bisexual men in Lambeth, Southwark and Lewisham. London: Sigma Research, London School of Hygiene and Tropical Medicine; 2014.Google Scholar
  50. 50.
    Ramchand R, Fisher MP, Griffin BA, Becker K, Iguch MY. Drug use among gay and bisexual men at weekend dance parties: the role of intentions and perceptions of peers’ behaviors. AIDS Behav. 2013;17:1540–9.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Winstock A. New health promotion for chemsex and γ-hydroxybutyrate (GHB). BMJ. 2015;25(351):h6281.CrossRefGoogle Scholar
  52. 52.
    EMCDDA. European information centre and database on new drugs. EMCDDA Early Warning System about GHB. 2011.Google Scholar
  53. 53.
    Degenhardt L, Darke S, Dillon P. GHB use among Australians: characteristics, use patterns and associated harm. Drug Alcohol Depend. 2002;67:89–94.PubMedCrossRefGoogle Scholar
  54. 54.
    Wisselink D, Mol A. GHB treatment demand in the Netherlands: major developments in treatment demand issues within the addiction care for GHB addiction 2007–2012. In: Landelijk Alcohol en Drugs Informatie Systeem (LADIS), 2013.Google Scholar
  55. 55.
    Van Laar MW, Van Ooyen-Houben MMJ, Cruts AAN, Meijer RF, Croes EA. Netherlands National Drug Monitor: NDM annual report 2016. Utrecht: Netherlands Institute of Mental Health and Addiction; 2016.Google Scholar
  56. 56.
    Dijkstra B, De Weert-van Oene GH, Verbrugge CAG, De Jong C. End report GHB detoxification with pharmaceutical GHB DeTiTap® monitor, in the Netherlands Addiction care. In: Nijmegen Institute for Scientist-Practitioners in Addiction, 2013.Google Scholar
  57. 57.
    Galloway GP, Frederick SL, Staggers F Jr. Physical dependence on sodium oxybate. Lancet. 1994;343(8888):57.PubMedCrossRefGoogle Scholar
  58. 58.
    Addolorato G, Stefanini CF, Gasbarrini G. Gamma-hydroxybutyric acid in the treatment of alcohol dependence: possible craving development for the drug. Addictioin. 1997;92(8):1035–6.CrossRefGoogle Scholar
  59. 59.
    McDaniel C, Miotto KA. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies. J Psychoactive Drugs. 2001;33:143–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Perez E, Chu J, Bania T. Seven days of gamma-hydroxybutyrate (GHB) use produces severe withdrawal. Ann Emerg Med. 2006;48(2):219–20.PubMedCrossRefGoogle Scholar
  61. 61.
    Bania T, Ashar T, Press G, Carey PM. Gamma-hydroxybutyric acid tolerance and withdrawal in a rat model. Acad Emerg Med. 2003;10(7):697–704.PubMedCrossRefGoogle Scholar
  62. 62.
    Goodwin A, Kaminski B, Griffiths R, Ator N, Weerts E. Intravenous self-administration of gamma-hydroxybutyrate (GHB) in baboons. Drug Alcohol Depend. 2011;114(2–3):217–24.PubMedGoogle Scholar
  63. 63.
    Goodwina A, Gibsonb KM, Weertsa EM. Physical dependence on gamma-hydroxybutrate (GHB) prodrug 1,4-butanediol (1,4-BD): time course and severity of withdrawal in baboons. Drug Alcohol Depend. 2013;132:427–33.CrossRefGoogle Scholar
  64. 64.
    Stein LA, Lebeau R, Clair M, Martin R, Bryant M, Storti S, Monti P. A web-based study of gamma hydroxybutyrate (GHB): patterns, experiences, and functions of use. Am J Addict. 2011;20(1):30–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Caputo F, Francini S, Stoppo M, Lorenzini F, Vignoli T, Del Re A, Comaschi C, Leggio L, Addolorato G, Zoli G, Bernardi M. Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: an open comparative study. J Psychopharmacol. 2009;23:883–90.PubMedCrossRefGoogle Scholar
  66. 66.
    Corkery J, Loi B, Claridge H, Goodair C, Corazza O, Elliott S, Schifano F. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use. Neurosci Biobehav Rev. 2015;53:52–78.PubMedCrossRefGoogle Scholar
  67. 67.
    Bornovalova MA, Lejuez CW, Daughters SB, Rosenthal ZM, Lynch TR. Impulsivity as a common process across borderline personality and substance use disorders. Clin Psychol Rev. 2005;25:790–812.PubMedCrossRefGoogle Scholar
  68. 68.
    Casillas A, Clark LA. Dependency, impulsivity, and selfharm: traits hypothesized to underlie the association between cluster B personality and substance use disorders. J Personal Disord. 2002;16:424–36.CrossRefGoogle Scholar
  69. 69.
    Kamal RM, Dijkstra BAG, de Weert-van Oene GH, van Duren, JAM, De Jong CAJ. Psychiatric comobidity, pychological distress and quality of life in gamma-hydroxybutyrate (GHB) dependent patients. J Addict Dis. 2016 (in press).Google Scholar
  70. 70.
    Bosch O, Quednow BB, Seifritz E, Wetter TC. Reconsidering GHB: orphan drug or new model antidepressant? J Psychopharmacol. 2012;26(5):618–28.PubMedCrossRefGoogle Scholar
  71. 71.
    Maremmani AGI, Bacciardi S, Rovai L, Rugani F, Dell’Osso L, Maremmani I. Sodium oxybate as off-label treatment for anxiety disorder: successful outcome in a low-energy anxious resistant patient. Addict Disord Treatm. 2015;14(4):198–202. doi: 10.1097/ADT.0000000000000055.CrossRefGoogle Scholar
  72. 72.
    Langford J, Gross WL. Psychosis in the context of sodium oxybate therapy. J Clin Sleep Med. 2011;7(6):665–6.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Ortega-Albás JJ, López-Bernabé R, García AL, Gómez JR. Suicidal ideation secondary to sodium oxybate. J Neuropsychiatry Clin Neurosci. 2010;22(3):352r.e326.Google Scholar
  74. 74.
    Rossetti AO, Heinzer RC, Tafti M, Buclin T. Rapid occurrence of depression following addition of sodium oxybate to modafinil. Sleep Med. 2010;11:497–501.CrossRefGoogle Scholar
  75. 75.
    Brunt TM, Koeter MW, Hertoghs N, van Noorden MS, van den Brink W. Sociodemographic and substance use characteristics of gamma hydroxybutyrate (GHB) dependent inpatients and associations with dependence severity. Drug Alcohol Depend. 2013;131(3):316–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Brailsford AD, Cowan DA, Kicman AT. Pharmacokinetic properties of γ-hydroxybutyrate (GHB) in whole blood, serum, and urine. J Anal Toxicol. 2012;36(2):88–95.PubMedCrossRefGoogle Scholar
  77. 77.
    Wojtowicz J. Withdrawal from gamma-hydroxybutyrate,1,4-butanediol and gamma-butyrolactone: a case report and systematic review. CJEM. 2008;10(1):69–74.PubMedCrossRefGoogle Scholar
  78. 78.
    Kamal R. The detoxification approach for patients with GHB dependence. Doctoral Thesis. Nijmegen: Radboud Universiteit Nijmegen; 2016.Google Scholar
  79. 79.
    Goodwin AK, Brown PR, Jansen EE, Jakobs C, Gibson KM, Weerts EM. Behavioral effects and pharmacokinetics of gamma-hydroxybutyrate (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons. Psychopharmacology (Berl). 2009;204(3):465–76.CrossRefGoogle Scholar
  80. 80.
    Choudhuri D, Cross S, Dargan PI, Wood DM, Ranjith G. Psychiatric aspects of acute withdrawal from gamma-hydroxybutyrate (GHB) and its analogue gamma-butyrolactone (GBL): implications for psychiatry services in the general hospital. Int J Psychiatry Clin Pract. 2013;17(2):154–6.PubMedCrossRefGoogle Scholar
  81. 81.
    Bowles T, Sommi RW, Amiri M. Successful management of prolonged g-hydroxybutyrate and alcohol withdrawal. Pharmacotherapy. 2001;21:254–7.PubMedCrossRefGoogle Scholar
  82. 82.
    Dyer J, Andrews KM. Gamma hydroxybutyrate withdrawal. J Toxicol Clin Toxicol. 1997;35:553–4.Google Scholar
  83. 83.
    de Jong C, Kamal R, Dijkstra BA, de Haan HA. Gamma-hydroxybutyrate detoxification by titration and tapering. Eur Addict Res. 2012;18(1):40–5.PubMedCrossRefGoogle Scholar
  84. 84.
    Catalano MC, Glass JM, Catalano G, Burrows SL, Lynn WA, Weitzner BS. Gamma butyrolactone (GBL) withdrawal syndromes. Psychosomatics. 2001;42(1):83–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Veerman SR, Dijkstra HN, Liefting-Kluft I. Life threatening symptoms of withdrawal of gamma-hydroxybutyrate. Tijdschr Psychiatr. 2010;52(6):411–6.PubMedGoogle Scholar
  86. 86.
    Friedman J, Westlake R, Furman M. ‘‘Grievous Bodily Harm’’: gamma hydroxybutyrate abuse leading to a Wernicke–Korsakoff syndrome. Neurology. 1996;46:469–71.PubMedCrossRefGoogle Scholar
  87. 87.
    Claussen M, Hassanpour K, Jenewein J, Boettger S. Catatonic stupor secondary to gamma-hydroxy-butyric acid (GHB)-dependence and -withdrawal syndrome. Psychiatria Danubina. 2014;26(4):358–9.PubMedGoogle Scholar
  88. 88.
    Chien J, Ostermann G, Turkel SB. Sodium oxybate-induced psychosis and suicide attempt in an 18-year-old girl. J Child Adolesc Psychopharmacol. 2013;23(4):300–1.PubMedCrossRefGoogle Scholar
  89. 89.
    Barker JC, Harris SL, Dyer JE. Experiences of gamma hydroxybutyrate (GHB) ingestion : a focus group study. J Psychoactive Drugs. 2007;39(2):115–29.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Miotto K, Roth B. Emerging trends in GHB withdrawl syndrome, detoxification. In: Texas Commissionon Alcohol and Drug Abuse (TCADA). Austin, Texas; 2001.Google Scholar
  91. 91.
    Rosenberg M, Deerfield LJ, Baruch E. Two cases of severe gamma-hydroxybutyrate withdrawal delirium on a psychiatric unit: recommendations for management. Am J Drug Alcohol Abuse. 2003;29:487–96.PubMedCrossRefGoogle Scholar
  92. 92.
    Mahr G, Bishop CL, Orringer DJ. Prolonged withdrawal from extreme gamma-hydroxybutyrate (GHB) abuse. Psychosomatics. 2001;42(5):439–40.PubMedCrossRefGoogle Scholar
  93. 93.
    Constantinides P, Vincent P. Chronic gamma-hydroxybutyric-acid use followed by gamma-hydroxybutyric-acid withdrawal mimic schizophrenia: a case report. Cases J. 2009;2:7520.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Kuiper MA, Peikert N, Boerma EC. Gamma-hydroxybutyrate withdrawal syndrome: a case report. Cases J. 2009;2:6530. doi: 10.1186/1757-1626-2-6530.
  95. 95.
    Freese TE, Miotto K, Reback CJ. The effects and consequences of selected club drugs. J Subst Abuse Treat. 2002;23(2):151–6.PubMedCrossRefGoogle Scholar
  96. 96.
    Domínguez I, Bruguera P, Balcells-Oliveró M, Batalla A. Depression following γ-hydroxybutyrate withdrawal: a case report. J Clin Psychopharmacol. 2015;35(5):618–9.PubMedCrossRefGoogle Scholar
  97. 97.
    Barth KS, Hines S, Albanese RP. Permanent neurologic damage from chronic gamma hydroxybutyrate abuse. Am J Addict. 2006;15(6):483–4.PubMedCrossRefGoogle Scholar
  98. 98.
    Mamelak M. Gammahydroxybutyrate: an endogenous regulator of energy metabolism. Neurosci Biobehav Rev. 1989;13:187–98.PubMedCrossRefGoogle Scholar
  99. 99.
    van Rij CM, Wilhelm AJ, van Loenen AC. Recognition and treatment of gamma hydroxybutyric acid poisoning. Ned Tijdschr Geneeskd. 2004;148(17):844–6.PubMedGoogle Scholar
  100. 100.
    van Noorden MS, Kamal R, de Jong CA, Vergouwen AC, Zitman F. Gamma-hydroxybutyric acid (GHB) dependence and the GHB withdrawal syndrome: diagnosis and treatment. Nederlands tijdschrift voor geneeskunde. 2010;154:A1286.PubMedGoogle Scholar
  101. 101.
    Palmer RB. Gamma-butyrolactone and 1,4-butanediol: abused analogues of gamma-hydroxybutyrate. Toxicol Rev. 2004;23(1):21–31.PubMedCrossRefGoogle Scholar
  102. 102.
    Colombo G, Agabio R, Lobina C, Reali R, Fadda F, Gessa GL. Cross-tolerance to ethanol and gamma-hydroxybutyric acid. Eur J Pharmacol. 1995;273(3):235–8.PubMedCrossRefGoogle Scholar
  103. 103.
    Mason PE, Kerns WP. Gamma hydroxybutyric acid (GHB) intoxication. Acad Emerg Med. 2002;9(7):730–9.PubMedCrossRefGoogle Scholar
  104. 104.
    Lettieri J, Fung HL. Absorption and first-pass metabolism of 14C-gamma-hydroxybutyric acid. Res Commun Chem Pathol Pharmacol. 1976;13(3):425–37.PubMedGoogle Scholar
  105. 105.
    Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med. 1999;159(18):2221–4.PubMedCrossRefGoogle Scholar
  106. 106.
    van Noorden MS, van Dongen LC, Zitman FG, Vergouwen TA. Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known. Gen Hosp Psychiatry. 2009;31(4):394–6.PubMedCrossRefGoogle Scholar
  107. 107.
    Supady A, Schwab T, Busch HJ. “Liquid ecstasy”: gamma-butyrolactone withdrawal delirium with rhabdomyolysis and dialysis dependent renal failure. Dtsch Med Wochenschr. 2009;134(18):935–7.PubMedCrossRefGoogle Scholar
  108. 108.
    Stijnenbosch PJ, Zuketto C, Beijaert PJ, Maat A. GHB withdrawal delirium [Article in Dutch]. Ned Tijdschr Geneeskd. 2010;154:A1086.PubMedGoogle Scholar
  109. 109.
    Sivilotti ML, Burns MJ, Aaron CK, Greenberg MJ. Pentobarbital for severe gamma-butyrolactone withdrawal. Ann Emerg Med. 2001;38(6):660–5.PubMedCrossRefGoogle Scholar
  110. 110.
    Schneir A, Ly BT, Clark RF. A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol. J Emerg Med. 2001;21(1):31–3.PubMedCrossRefGoogle Scholar
  111. 111.
    Miglani JS, Kim KY, Chahil R. Gamma-hydroxy butyrate withdrawal delirium: a case report. Gen Hosp Psychiatry. 2000;22(3):213–5.PubMedCrossRefGoogle Scholar
  112. 112.
    Kamal R, van Noorden MS, Dijkstra BA, Mauritz R, de Jong C. A case series of pharmaceutical gamma-hydroxybutyrate in 3 patients with severe benzodiazepine-resistant gamma-hydroxybutyrate withdrawal in the hospital. Psychosomatics. 2014;56(4):404–9.PubMedGoogle Scholar
  113. 113.
    Hutto B, Fairchild A, Bright R. Gamma-hydroxybutyrate withdrawal and chloral hydrate. Am J Psychiatry. 2000;157(10):1706.PubMedCrossRefGoogle Scholar
  114. 114.
    van Raay MEJ. GHB-onttrekkingsverschijnselen behandeled met diazepam, baclofen en propranolol. Psyfar. 2012;2:22–5.Google Scholar
  115. 115.
    Bell J, Collins R. Gamma-butyrolactone (GBL) dependence and withdrawal. Addiction. 2011;106(2):442–7.PubMedCrossRefGoogle Scholar
  116. 116.
    de Weert-van Oene GH, Schellekens AF, Dijkstra BA, Kamal R, de Jong CA. Detoxification of patients with GHB dependence. Tijdschr Psychiatr Dutch. 2013;55(11):885–90.Google Scholar
  117. 117.
    Stalcup J, Wylie B, Stalcup SA. Outpatient treatment for GHB dependence. In: Porrata T, editor. “G’d Up” 24/7 the GHB addiction guide. USA: LawTech Publishing; 2007.Google Scholar
  118. 118.
    Chin R. A case of severe withdrawal from gamma-hydroxybutyrate. Ann Emerg Med. 2001;37(5):551–2.PubMedCrossRefGoogle Scholar
  119. 119.
    Bennett WRM, Wilson LG, Roy-Byrne PP. Gamma-hydroxybutyric acid (GHB) withdrawal: a case report. J Psychoact Drugs. 2007;39(3):293–6.CrossRefGoogle Scholar
  120. 120.
    Eiden C, Capdevielle D, Deddouche C, Boulenger JP, Blayac JP, Peyrière H. Neuroleptic malignant syndrome-like reaction precipitated by antipsychotics in a patient with gamma-butyrolactone withdrawal. J Addict Med. 2011;5(4):302–3.PubMedCrossRefGoogle Scholar
  121. 121.
    Zepf FD, Holtmann M, Duketis E, Maier J, Radeloff D, Schirman S, Wagner A, Poustka F, Wöckel L. Withdrawal syndrome after abuse of GHB (-hydroxybutyrate) and its physiological precursors—its relevance for child and adolescent psychiatrists (in German). Z Kinder Jugendpsychiatr Psychother. 2009;37:413–20.PubMedCrossRefGoogle Scholar
  122. 122.
    Taylor CP. Mechanisms of action of gabapentin. Rev Neurol (Paris). 1997;153(Suppl 1):S39–45.Google Scholar
  123. 123.
    Glasper A, McDonough M, Bearn J. Within-patient variability in clinical presentation of gamma-hydroxybutyrate withdrawal: a case report. Eur Addict Res. 2005;11(3):152–4.PubMedCrossRefGoogle Scholar
  124. 124.
    Boonstra M. Ontwenning van ghb: een voorbeeldpraktijk (detoxification of GHB: a model for clinical practice). Verslaving. 2011;7:3–15.CrossRefGoogle Scholar
  125. 125.
    Ghio L, Cervetti A, Respino M, Belvederi Murri M, Amore M. Management and treatment of gamma butyrolactone withdrawal syndrome: a case report and review. J Psychiatr Pract. 2014;20(4):294–300.PubMedCrossRefGoogle Scholar
  126. 126.
    Tarabar AF, Nelson LS. The gamma-hydroxybutyrate withdrawal syndrome. Toxicol Rev. 2004;23:45–9.PubMedCrossRefGoogle Scholar
  127. 127.
    Nardou R, Yamamoto S, Bhar A, Burnashev N, Ben-Ari Y, Khalilov I. Phenobarbital but not diazepam reduces AMPA/kainite receptor mediated currents and exerts opposite actions on initial seizures in the neonatal rat hippocampus. Front Cell Neurosci. 2011;5:16. doi: 10.3389/fncel.2011.00016
  128. 128.
    Wong A, Benedict NJ, Lohr BR, Pizon AF, Kane-Gill SL. Management of benzodiazepine-resistant alcohol withdrawal across a healthcare system: benzodiazepine dose-escalation with or without propofol. Drug Alcohol Depend. 2015;154:296–9.PubMedCrossRefGoogle Scholar
  129. 129.
    Herold AH, Sneed KB. Treatment of a young adult taking gammabutyrolactone (GBL) in a primary care clinic. J Am Board Fam Pract. 2002;15:161–3.PubMedGoogle Scholar
  130. 130.
    Meyer R, Jenewein J, Boettger S. Management of gamma-butyrolactone dependence with assisted self-administration of GBL. Case Rep Neurol Med. 2014;2014:3. doi: 10.1155/2014/485178
  131. 131.
    LeTourneau J, Hagg D, Smith S. Baclofen and gamma-hydroxybutyrate withdrawal. Neurocrit Care. 2008;8(3):430–3.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    de Jong CAJ, van Hoek AFM, Jongerhuis M. Guideline detox: responsible withdrawal by out- or inpatient detoxification. Amersfoort: Resultaten Scoren; 2004.Google Scholar
  133. 133.
    Kamal RM, van Iwaarden S, Dijkstra BA, de Jong CA. Decision rules for GHB (γ-hydroxybutyric acid) detoxification: a vignette study. Drug Alcohol Depend. 2014;135:146–51.PubMedCrossRefGoogle Scholar
  134. 134.
    Kamal R, De Jong CAJ. Practice-based recommendations for the detoxification of patiënts with GHB abuse disorders in an outpatient setting. Nijmegen: Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA); 2013.Google Scholar
  135. 135.
    Kamal RM, Dijkstra BA, Loonen AJ, De Jong CA. The effect of co-occurring substance use on gamma-hydroxybutyric acid withdrawal syndrome. J Addict Med. 2016;10(4):229–35Google Scholar
  136. 136.
    Beurmanjer H, Verbrugge CAG, Schrijen S, Schellekens AS, DeJong CAJ, Dijkstra BAG. Treatment of patients with GHB dependence. End report of the GHB Monitor 2.0 [ reprort in Dutch]. Nijmegen: Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA); 2016.Google Scholar
  137. 137.
    Laborit H. Sodium 4-hydroxybutyrate. Intl J Neuropharmacol. 1964;3:433–49.CrossRefGoogle Scholar
  138. 138.
    Dijkstra B, De Weert-van Oene GH, Verbrugge CAG, De Jong C. GHB detoxificatie met farmaceutische GHB. Eindrapportage van de monitoring van DeTiTap® in de Nederlandse verslavingszorg (end report GHB detoxification with pharmaceutical GHB monitor, in the Netherlands addiction care). Nijmegen: Nijmegen Institute for Scientist-Practitioners in Addiction; 2013.Google Scholar
  139. 139.
    Kamal R, Loonen AJ, Dijkstra BA, De Jong CA. Baclofen as relapse prevention in the treatment of gamma-hydroxybutyrate dependence: a case series. J Clin Psychopharmacol. 2015;35(3):313–8.PubMedCrossRefGoogle Scholar
  140. 140.
    Kamal RM, Schellekens A, De Jong CA, Dijkstra BA. Baclofen as relapse prevention in the treatment of gamma-hydroxybutyrate (GHB) dependence: an open label study. BMC Psychiatry. 2015;28(15):91.CrossRefGoogle Scholar
  141. 141.
    Li J, Stokes SA, Woeckener A. A tale of novel intoxication: seven cases of gamma hydroxybutyric acid overdose. Ann Emerg Med. 1998;31:723–8.PubMedCrossRefGoogle Scholar
  142. 142.
    Sigel E, Steinmann ME. Structure, function, and modulation of GABA(A) receptors. J Biol Chem. 2012;287(48):40224–31.PubMedPubMedCentralCrossRefGoogle Scholar
  143. 143.
    Lingford-Hughes A. Improving GHB withdrawal with baclofen (The GHB Trial). http://www.hra.nhs.uk/news/research-summaries/the-ghb-trial/#sthash.4o74rx8G.dpuf. 2014–2016.

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Rama M. Kamal
    • 1
    • 2
  • Martijn S. van Noorden
    • 3
  • Wim Wannet
    • 4
  • Harmen Beurmanjer
    • 1
    • 2
  • Boukje A. G. Dijkstra
    • 1
  • Arnt Schellekens
    • 1
  1. 1.Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA)NijmegenThe Netherlands
  2. 2.Novadic-Kentron Addiction Care NetworkVughtThe Netherlands
  3. 3.Leiden University Medical CentreLeidenThe Netherlands
  4. 4.Scientific Research Committee IrisZorgArnhemThe Netherlands

Personalised recommendations